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Summary Zonisamide is a synthetic 1,2-benzisoxazole-3-methanesulfonamide with
anticonvulsant properties. The sulfamoyl group on zonisamide was expected to sup-
press seizures in a manner similar to another sulfonamide analogue, acetazolamide,
through inhibition of carbonic anhydrase. However, this does not appear to be the
primary mechanism of action since zonisamide requires much higher doses than ac-
etazolamide to achieve equivalent titration in vivo.
Studies with cultured neurons indicate that zonisamide blocks repetitive ﬁring of
voltage-sensitive sodium channels and reduces voltage-sensitive T-type calcium cur-
rents without affecting L-type calcium currents. Its dual mechanism of action may
explain its efﬁcacy in patients resistant to other antiepileptic drugs (AEDs).
Zonisamide has a pharmacokinetic proﬁle favorable for clinical use. It is rapidly
and completely absorbed and has a long half-life (63—69 h in healthy volunteers)
which allows twice-daily, or even once-daily, dosing. Zonisamide is not highly bound
to plasma proteins. Consequently, it does not affect protein binding of other highly
protein-bound AEDs. Furthermore, zonisamide does not induce its own metabolism
and does not induce liver enzymes. However, since zonisamide is metabolized by
cytochrome P450, liver enzyme-inducing AEDs will increase zonisamide clearance,
and dosage adjustments may be necessary when it is used in combination with certain
AEDs.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Zonisamide is a novel antiepileptic drug (AED) that
was developed in search of a less toxic, more ef-
fective anticonvulsant. The drug has been used in
Japan since 1989, and is effective for simple and
complex partial seizures, generalized tonic-clonic
seizures, myoclonic epilepsies, Lennox—Gastaut
syndrome, and infantile spasms.1,2 In Japan, zon-
isamide is currently indicated for monotherapy and
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adjunctive therapy for partial onset and general-
ized onset seizures in adults and children. In the
United States, zonisamide was approved by the
Food and Drug Administration (FDA) in 2000 as an
adjunctive treatment for partial seizures.
The drug’s broad spectrum of activity and favor-
able pharmacokinetic proﬁle offer certain advan-
tages in the epilepsy treatment armamentarium.
Chemically distinct from other AEDs, zonisamide
has been shown to be effective in patients whose
seizures are resistant to other AEDs. Zonisamide’s
long plasma elimination half-life has allowed it to
be used in a once-daily or twice-daily treatment
regimen in Japan.2
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Figure 1 Molecular structure of zonisamide.
Chemistry
The molecular formula of zonisamide is C8H8N2O3S
(Fig. 1). Zonisamide is classiﬁed as a member of
the methanesulfonamide group even though it has a
sulfamoyl group in common with acetazolamide, an
arylsulfonamide analog that also has anticonvulsant
properties.2,3
Mechanism of action
The anticonvulsant activity of zonisamide, which
shares pharmacological properties with phenytoin,
carbamazepine, and sodium valproate, has been
demonstrated in many animal and cultured neuron
models, as well as in clinical studies.
Like phenytoin and carbamazepine, zonisamide
blocks the spread or propagation of seizure dis-
charges. Zonisamide has been shown to prevent
the tonic extensor components of maximal elec-
troshock seizures in mice, rats, rabbits, and dogs;3
restrict the spread of focal seizures evoked by
electrical stimulation of the visual cortex in cats;4
and prevent the propagation of seizures from the
cortex to subcortical structures, which are evoked
by cortical freezing in cats,4 and by electrical
stimulation in visual cortex-kindled cats.5
It is believed that zonisamide’s effect on the
propagation of seizure discharges involves blocking
the repetitive ﬁring of voltage-sensitive sodium
channels, and reducing voltage-sensitive T-type
calcium currents without affecting L-type calcium
currents. These mechanisms stabilize neuronal
membranes and suppress neuronal hypersynchro-
nization, leading to the suppression of partial
seizures and generalized tonic—clonic seizures in
humans.2,6
Zonisamide possesses mechanisms of action that
are similar to those of sodium valproate, e.g., sup-
pression of epileptogenic activity and depression of
neuronal responses. These mechanisms are thought
to contribute to the suppression of absence and my-
oclonic seizures.2
Since zonisamide has a sulfamoyl group on its side
chain, it was anticipated that the drug might ex-
ert its anticonvulsant effects in a manner similar
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Figure 2 Hydroxyl radical scavenging activity of zon-
isamide.
to the related compound acetazolamide, which in-
hibits seizure activity, i.e. via inhibition of carbonic
anhydrase. However, when zonisamide was com-
pared with acetazolamide in vivo, zonisamide had
only weak carbonic anhydrase inhibiting activity,
requiring 100—1000 times higher doses than aceta-
zolamide to achieve equivalent inhibition.3 Thus,
carbonic anhydrase inhibition was ruled out as the
primary mechanism of action of zonisamide.2 The
presence of a methylene group on zonisamide’s side
chain may explain the differences in carbonic an-
hydrase inhibition.
Unlike some other AEDs, zonisamide does not
appear to affect the synaptic activity induced by
-aminobutyric acid (GABA) or glutamate,2 as do
other AEDs.
One study has suggested that the anticonvulsant
effect of zonisamide may also involve protecting
neurons from free radical damage. In this in vitro
study, as zonisamide dosage increased, activity of
hydroxyl and nitric oxide radicals decreased (Figs. 2
and 3). Hydroxyl radicals are thought to be the most
harmful radical for neuromembranes. Nitric oxide,
a messenger molecule in the central nervous sys-
tem, may also cause pathological nervous tissue
damage under some conditions.7
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Figure 3 Nitric oxide scavenging activity of zonisamide.
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In summary, zonisamide is believed to exert anti-
convulsant effects by blocking sustained, repetitive
neuronal ﬁring via a blockade of voltage-sensitive
sodium and by reducing voltage-sensitive T-type
calcium channels. Zonisamide has no effect on
neuronal responses to GABA or glutamate, and its
activity is not due to carbonic anhydrase inhibition.
Pharmacokinetics
Zonisamide is rapidly and completely absorbed,
with peak plasma concentrations occurring 2—4h
following 100- to 400mg oral doses in healthy
volunteers.6 The mean plasma elimination half-life
is long-about 60 h in noninduced subjects after sin-
gle and multiple doses,6 with ranges from 52 to
69 h reported.8
Steady state plasma concentrations of zon-
isamide in placebo-controlled studies ranged
from 1.9 to 55.3g/mL (median, 18g/mL) after
10—12 days of dosing.6 The plasma or serum lev-
els of zonisamide have been shown to be linearly
dose-related in adult and pediatric patients.2
At zonisamide concentrations of 1.0—7.0g/mL,
the drug is only about 40% bound to human plasma
proteins.6 However, zonisamide has a high binding
afﬁnity for red blood cells (RBCs), and a marked
concentration of zonisamide is observed in human
red blood cells.2 The afﬁnity of zonisamide for RBCs
is 8 times higher than that for plasma proteins,6 and
is dependent on the extracellular concentration of
zonisamide.2 For plasma concentrations >5g/mL,
the zonisamide plasma versus erythrocyte concen-
tration relationship appears to be relatively linear
due to a dominant passive-diffusion distribution
process.
Zonisamide undergoes acetylation to form
N-acetyl zonisamide, and reduction to form the
Figure 4 Enzymic cytochrome P450 reduction and nonenzymic hydrolysis.
open ring metabolite, 2-sulfamoylacetyl phenol
(SMAP) (Fig. 4).9
Reduction of zonisamide to SMAP is mediated by
the cytochrome P450 isozyme 3A4.10 Zonisamide
does not induce its own metabolism and does not
induce liver enzymes.8
Urine is the major route of zonisamide excretion
in humans; excretion in feces is a minor elimination
route.2 Following multiple dosing, 62% of the radio-
labelled dose was recovered in the urine, with 3% in
the feces. Of the excreted dose, 35% was recovered
as zonisamide, 15% as N-acetyl zonisamide, and 50%
as the glucuronide of SMAP.6
Drug interactions
Since zonisamide is not highly bound to plasma pro-
teins, it does not affect protein binding of other
highly protein-bound AEDs. Protein binding of zon-
isamide is unaffected in the presence of therapeu-
tic concentrations of phenytoin, phenobarbital, or
carbamazepine.6
Since zonisamide is metabolized by the cy-
tochrome P450 3A4, other drugs that induce or
inhibit this enzyme may induce or inhibit zon-
isamide metabolism. Concomitant administration
of phenytoin and carbamazepine increases zon-
isamide clearance from 0.32 to 0.51mL/(min kg).
The plasma elimination half-life of zonisamide is
decreased to 27 h by phenytoin, to 38 h by pheno-
barbital and carbamazepine, and to 46 h by sodium
valproate.6 The differential effects of phenytoin
and carbamazepine were also documented in a
study where zonisamide was administered to pa-
tients receiving phenytoin or carbamazepine as
monotherapy. The area under the curve (AUC) of
zonisamide was 20% higher in the carbamazepine
group compared to the phenytoin group (Table 1).11
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Table 1 Median pharmacokinetic parameters for zonisamide in plasma (ranges).10
Concurrent medication Cmax (g/mL) Tmax (h) AUCa (g/mL) Cl/F (mL/h/kg) t1/2 (h)
Phenytoin 4.8 (3.8—5.9) 2.5 (1.9—4.9) 171 (130—245) 33.9 (19.3—37.4) 27.1 (20.7—34.9)
Carbamazepine 5.2 (3.1—6.6) 2.5 (2—4) 242 (215—386) 20.6 (14.8—26.8) 36.4 (31.8—54.6)
Cmax, maximum concentration; Tmax, time to reach Cmax; AUC, area under the curve; Cl/F, oral clearance; t1/2,
half-life.
a Phenytoin median = Carbamazepine median, Mann—Whitney U-test, P < 0.05.
Table 2 Effect of concomitant administration of
AEDs on zonisamide steady state.11
Medications n C/Da ratio of
zonisamide
Zonisamide alone 28 4.71 ± 0.21
Zonisamide + phenobarbital 11 3.33 ± 0.22
Zonisamide + phenytoin 14 2.88 ± 0.39
Zonisamide + sodium valproate 24 3.79 ± 0.16
Zonisamide + clonazepam 8 4.31 ± 0.49
Carbamazepine alone 34
Zonisamide + carbamazepine 17 2.89 ± 0.22
Values are expressed as means ± S.E.
a C/D, concentration-to-dose.
Concomitant administration of zonisamide with
phenobarbital, phenytoin, or carbamazepine signif-
icantly decreased the concentration-to-dose (C/D)
ratio (ratio of the steady-state plasma concen-
tration to the administered dose) of zonisamide,
whereas clonazepam and sodium valproate did
not change the C/D ratio (Table 2). In one clin-
ical trial, the ratio of plasma concentration of
carbamazepine-10,11-epoxide, the major active
metabolite of carbamazepine, to the plasma con-
centration of carbamazepine, was decreased by
concomitant administration of zonisamide, but
the signiﬁcance of this is not clear.12 A number of
studies have evaluated the effect of zonisamide
on the pharmacokinetics of other drugs, including
AEDs, and have concluded that concomitant ad-
ministration of zonisamide does not affect serum
concentrations of carbamazepine, phenytoin,
or sodium valproate to any clinically signiﬁcant
extent.
Conclusions
The pharmacokinetic proﬁle of zonisamide is favor-
able for clinical treatment of seizures. Zonisamide
is rapidly and completely absorbed. Its long plasma
elimination half-life allows for twice-daily, or even
once-daily, dosing. Its dual mechanism of action
may account for its efﬁcacy in patients resistant to
other AEDs.
Zonisamide does not affect protein binding of
other highly protein-bound AEDs, such as phenytoin
or carbamazepine. However, liver enzyme-inducing
AEDs (such as phenytoin, carbamazepine, sodium
valproate, or phenobarbital) will increase the
plasma clearance of zonisamide, shorten its
half-life, and lower its concentration/dose ratio.
Therefore, dosage adjustments may be neces-
sary to maintain therapeutic levels of the drug
when it is used in combination with certain
AEDs.
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